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Abstract Most countries in Western Europe are currently
free of rabies in terrestrial mammals. Nevertheless, rabies
remains a residual risk to public health due to the natural
circulation of bat-specific viruses, such as European bat
lyssaviruses (EBLVs). European bat lyssavirus types 1 and
2 (EBLV-1 and EBLV-2) are widely distributed throughout
Europe, but little is known of their true prevalence and
epidemiology. We report that only three out of 837 brains
taken from bats submitted to the Swiss Rabies Centre
between 1976 and 2009 were found by immunofluores-
cence (FAT) to be positive for EBLVs. All three positive
cases were in Myotis daubentoni, from 1992, 1993 and
2002. In addition to this passive surveillance, we undertook
a targeted survey in 2009, aimed at detecting lyssaviruses
in live bats in Switzerland. A total of 237 bats of the
species M. daubentoni, Myotis myotis, Eptesicus serotinus
and Nyctalus noctula were captured at different sites in
western Switzerland. Oropharyngeal swabs and blood from
each individual were analysed by RT-PCR and rapid
fluorescent focus inhibition test (RFFIT), respectively.
RNA corresponding to EBLV-2 was detected from oro-
pharyngeal swabs of a single M. daubentoni bat, but no
infectious virus was found. Molecular phylogenetic anal-
ysis revealed that the corresponding sequence was closely
related to the other EBLV-2 sequences identified in pre-
vious rabies isolates from Swiss bats (particularly to that
found at Geneva in 2002). Three M. daubentoni bats were
found to be seropositive by RFFIT. In conclusion, even
though the prevalence is low in Switzerland, continuous
management and surveillance are required to assess the
potential risk to public health.
Introduction
Bats across the world have been recognized as reservoir
hosts for a number of emerging infectious diseases and
zoonoses that can cross the species barriers and infect other
mammals, including humans (reviewed in [1, 2]). Rabies is
the oldest recorded zoonosis, and still the most important
one using bats as a reservoir host [3].
Rabies is a worldwide viral zoonosis that can infect all
mammals, including humans (for a recent review, see ref.
[4]). The infection is due to lyssaviruses (genus Lyssavirus,
family Rhabdoviridae), and several species of carnivore,
apart from bats, act as reservoirs. There are currently 11
recognized species [5–7] and one newly described geno-
type in the genus Lyssavirus [8], including the European
bat lyssavirus type 1 (EBLV-1, genotype 5) and the
European bat lyssavirus type 2 (EBLV-2; genotype 6). All
but one genotype (Mokola virus) have been found in bats
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[9]. The first rabid insectivorous bat in Europe was recor-
ded in Hamburg, Germany, in 1954 [10]. Over 850 cases of
rabies-positive bats have subsequently been recorded
between 1977 and 2008 [11]. Most of the cases were
EBLV-1, and 95% of all reported EBLV-1 infections were
found in serotine bats, Eptesicus serotinus [12, 13]. By
contrast, EBLV-2 has been discovered only 20 times to
date, mostly in Daubenton’s bats, Myotis daubentoni, in
Finland [14], Switzerland [15], the United Kingdom [16,
17] and Germany [18] and in pond bats, Myotis dasycneme,
in the Netherlands [12]. So far, the Netherlands and
Germany are the only countries where both genotypes have
been isolated from rabies-positive bats [12, 18].
EBLVs are of public health concern, as both EBLV-1 and
EBLV-2 have been transmitted to humans and resulted in
fatalities (for a recent review, see ref. [4]). In 1985, a bat
researcher in Finland died of rabies encephalitis caused by
EBLV-2b [19]. However, the geographical location of the
infection could not be pinpointed because this researcher had
handled bats in several countries, including Switzerland,
during the previous years. In a targeted surveillance,
undertaken in 1986 in southern Finland, no lyssavirus
infection could be detected from a sample of 183 bats [20].
The first EBLV-2-positive Daubenton’s bat in Finland was
finally reported in 2009 [14]. Phylogenetic analysis showed
that the EBLV-2b isolate from the human case in 1985 was
most closely related to the recent Finnish bat isolate, indi-
cating that the source of the human infection might have
been in Finland (see [14]).
However, our knowledge on prevalence epidemiology
and pathogenesis of EBLVs remains partial and enigmatic.
Clinically silent rabies infections have been described in
several bat species worldwide [21–23]. Viral RNA has
been detected in the saliva, blood and various organs of
healthy bats captured in field colonies. The excretion of
viral RNA in the saliva may persist and fluctuate over time
[24]. Similarly, antiviral antibodies were also detected in
healthy captured bats. On the other hand, most cases
detected so far have been in diseased or dead animals, and
experimental infection of bats usually leads to short
excretion and fast death [22, 25]. Nevertheless, the risk of
rabies transmission to humans is real and raises important
implications for bat management and bat specialists pro-
tection [26].
Herein, we present a compilation of the passive sur-
veillance conducted so far and the results of a recent tar-
geted survey in four bat species living in western
Switzerland. In the targeted survey, we focused on
M. daubentoni, M. myotis and E. serotinus, as members of
these three species have been found to be infected with
rabies virus in European countries, and on Nyctalus noc-
tula, as this species migrates over long distances [27] and
could potentially disseminate the disease over a large
geographical range while infected. Myotis dasycneme is
also a potential host for EBLV-2, but the species is not
found in Switzerland.
Materials and methods
Sample collection
(a) Passive surveillance
Passive surveillance for EBLVs, based on dead and dis-
eased animals with clinical suspicion, was initiated in
Switzerland in 1966 by the Swiss Rabies Centre. Dead and
freshly euthanized animals were submitted to the Swiss
Rabies Centre by bat conservationists, museum curators,
veterinarians or the general public.
(b) Active surveillance
Bats (M. daubentoni, M. myotis, E. serotinus and N. noc-
tula) were captured in 2009 at 12 different locations around
Lake Geneva and close to Lake Neuchaˆtel in the cantons of
Vaud, Geneva and Fribourg, in Switzerland. Greater
mouse-eared bats were captured either inside reproductive
colonies (n = 40) or at the entrance of caves, noctule bats
inside pre-hibernating colonies (nest boxes), serotine bats
at the entrance of caves and Daubenton’s bats while flying
over rivers using mist nests or harptraps. The sex, repro-
ductive status, age, body mass, forearm length and general
body condition were recorded. Signs of poor health, such
as poor condition of fur, state of emaciation, abnormal
behaviour, parasitic load and excessively injured wings
(rips, tears and punctures) were also recorded. A uniquely
numbered bat ring (Museum of Natural History, Geneva,
Switzerland) was fitted on each bat for future individual
recognition. Capturing, handling, ringing and sampling of
bats were done under the current laws of Switzerland
(Authorization of Consumer and Veterinary Services of
Canton of Vaud no. 2203, Switzerland).
Two oropharyngeal swabs (one dry, one wet) were taken
from each bat to collect saliva in order to determine the
presence of EBLV. The swabs were then immediately
placed on dry ice (4C) and brought back to the laboratory.
All swabs were stored at -80C until analysis.
Blood samples were taken with a 0.55 9 25 mm needle
(Romedic SA, Lausanne, Switzerland) from the uropatagial
vein and collected in a Microvette CB300 capillary tube
(Sarstedt, Nu¨mbrecht, Germany) with EDTA. The volume
of blood sampled varied between 5 and 100 ll. Haemo-
static cotton (Flawa, Flawil, Switzerland) was then applied
to the puncture site to prevent further bleeding and to
facilitate healing. The bat was then kept for about 15 min
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after taking a blood sample to let it calm down. The health
condition of each bat was assessed before its release. Blood
samples were stored at *2C in the field for a few hours.
In the laboratory, samples were centrifuged at 1,4009g for
15 min, and the plasma was stored at -80C until analysis.
Sample analysis
(a) Detection of EBLV antigens
The standard fluorescent antibody test (FAT) was per-
formed on the brain tissues of all individuals from the
passive surveillance programme using a previously
described method [28].
(b) Isolation of infectious virus
Virus isolation was performed using a rabies tissue-culture
infection test (RTCIT) with four consecutive passages in
neuroblastoma cells (MNA 42/13, kindly provided by
Dr. W. Mu¨ller, Tu¨bingen, 1994) inoculated with 20% brain
or saliva suspension, followed by immunofluorescence
staining for rabies virus after each passage [29, 30].
(c) Detection of EBLV RNA
All saliva samples were analysed by RT-PCR to detect the
presence of host and viral RNA. Five hundred microlitres
of RNA Storage Solution (Ambion, Foster City, CA, USA)
was added to either the wet or the dry frozen swab of each
of the 237 bats sampled. The swabs were then thawed for
10 min at room temperature, vortexed vigorously for
1 min, and then centrifuged at 5,000 rpm for 10 min. RNA
was extracted from 140 ll of the supernatant using a
QIAmp Viral RNA Kit (QIAgen, Germantown, MD, USA).
To detect viral RNA, a reverse transcription PCR (RT-
PCR) was performed using a OneStep RT-PCR Kit
(QIAgen, Germantown, MD, USA), following a protocol
adapted from Vazquez-Moron et al. [31]. The primers
GRAB1F and GRAB1R, designed by Vazquez-Moron
et al. [31], bind to a conserved region of the nucleoprotein
gene of the first seven recognized lyssavirus genotypes
(260 bp). Nested PCR was performed using the primers
GRAB2F and GRAB2R [31]. All amplifications were
performed in a 2720 Thermal Cycler (Applied Biosystems,
Foster City, CA, USA). PCR products were visualised
under UV light after gel electrophoresis in 1.5% agarose.
The interpretation of PCR results assumed that each swab
contained host material (host-derived RNA) from the oral
cavity. In order to prevent false negative detection due to
absence of host material, a second RT-PCR was conducted
on each sample, using specific primers that bind to the
mammalian glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene according to Ravazzolo et al. [32]. The RT-
PCR reaction was conducted in a total volume of 50 ll, using
a OneStep RT-PCR Kit (QIAgen, Germantown, MD, USA)
as described above for the first round of nested PCR. PCR
products were run on ethidium-bromide-stained poly-
acrylamide gels and visualized under UV light. GAPDH-
positive samples showed a specific band at 125 bp.
Positive (CVS) and negative (RNA Storage Solution or
H2O) controls were added at each of the following steps:
RNA extraction, RT-PCR, and nested PCR. When a saliva
sample was found to be positive, the second corresponding
saliva sample from that bat was also tested following the
procedure described above.
(d) Detection of EBLV antibodies
A microtitre adaptation of RFFIT in 96-well microtitre
tissue culture trays was performed essentially as described
[33, 34]. The samples were serially diluted from 1:25 to
1:625 in BHK-21 cell culture medium. A pool of human
sera calibrated with the second International Standard
Preparation for Rabies Immunoglobulins was used as a
control standard [35]. CVS-11 (Challenge Virus Strain;
[36]) or EBLV-2 virus was used as challenge virus. The
virus-neutralizing antibody (VNA) titres were calculated
according to Spearman and Kaerber [37, 38] by extrapo-
lating the dilution of the sample that reduces the number of
fluorescent microscopic fields to 50%. International units
(IU) were determined using a standard control (9.0 IU/ml).
Phylogenetic reconstruction
The 220-bp nucleotide sequences of the nucleoprotein gene
obtained in this study were edited using MEGA v 4.0 [39],
aligned using CLUSTAL 2.0.12 [40], visually inspected and
manually corrected. Additional sequences were retrieved
from GenBank (see Table 1).
Phylogenetic trees were constructed using two different
methods: maximum likelihood (ML) and Bayesian analysis
(BA). The model of DNA substitution was selected using
jModeltest v 0.1.1 [41] and the minimum Akaike infor-
mation criterion value. The HKY85 ? G model best fitted
the data. ML heuristic searches and bootstrap analyses
(1,000 replicates) were performed using PHYML v 3.0 [42].
The BA was performed with MrBayes v 3.1.2 [43, 44].
Two independent runs were performed, each of them
consisting of four parallel MCMC chains of five million
generations, allowing a good convergence of the indepen-
dent runs. After having visualised the parameters and
controlled for a burn-in period using the software TRACER
v 1.5 [45], 10% of the trees were discarded as burn-in
period. The remaining trees were used to construct a 50%
major-consensus tree.
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Results
Passive surveillance and detection of EBLV antigens
A total of 837 bat brain specimens were analysed in FAT/
RTCIT between 1976 and 2009 (Table 2). Daubenton’s
bat was the only species found to be positive for lyssa-
virus infection. Three cases of EBLV-2b have been
identified, one on August 24, 1992, in Plaffeien, canton of
Fribourg, one on July 10, 1993, in Versoix, canton
of Geneva, and one on September 2, 2002, in the city of
Geneva, canton of Geneva. No bat infected with EBLV-1
has been recorded. The numbers of bats submitted
annually varied from 0 to 5 from 1976 to 1985 to 11 to
90 since 1986. Almost 50% of the submitted specimens
were pipistrelles (Pipistrellus spp.). Notably, only 64 bats
were M. daubentoni (7.6%), and 21 were Eptesicus
serotinus (2.5%), which are the two main vectors of
EBLVs. The surveillance intensity was regionally biased,
with significantly higher numbers of submissions from
large agglomerations than from the countryside, e.g. the
area around the first Swiss case in the canton of Fribourg
(Fig. 1). Overall, the area covered roughly corresponds to
the most suitable habitats for bats in Switzerland, avoid-
ing higher mountainous regions.
Detection of EBLV antibodies
A minimum volume of 5 ll of plasma is necessary to proceed
with RFFIT. Thus, only 202 bats out of the 237 sampled were
subjected to the analysis (124/148 M. daubentoni, 47/51 M.
myotis, 17/23 E. serotinus and 14/15 N. noctula; Table 3).
All samples were tested individually for antibody with
CVS and/or EBLV-2b as challenge virus.
One hundred fifty specimens (109 M. daubentoni, 24 M.
myotis, 10 E. serotinus and 7 N. noctula) were tested in the
assay with CVS as the challenge virus, out of which 130
were tested at initial dilutions of 1:25, and 20 at 1:125.
One hundred sixty samples, including 94 M. daubentoni,
46 M. myotis, 11 E. serotinus and 9 N. noctula, were also
Table 1 The site of collection,
year of isolation, bat species and
GenBank accession number for
each EBLV strain used in the
phylogenetic analyses
NA information not available
a This study
Virus Year of isolation Locality Country Bat species Accession no.
EBLV-2
70 2009 Genthod (GE) Switzerland M.daubentoni HM067110a
118 2002 Geneva (GE) Switzerland M.daubentoni HM067109a
RV1333 2002 NA United Kingdom M.daubentoni EF157977
1392 1993 Versoix (GE) Switzerland M.daubentoni HM067108a
9375 1993 Roden The Netherlands M.dasycneme AY863404
1814 1992 Plaffeien (FR) Switzerland M.daubentoni HM067107a
94112 1989 Andijk The Netherlands M.dasycneme AY863405
9018 1987 Wommels The Netherlands M.dasycneme AY863403
9007 1986 Helsinki Finland Human AY863406
EBLV-1
102 2000 Haute-Marne France E.serotinus AY863399
9477 1986 Niedersachsen Germany E.serotinus AY863357
Table 2 The number of individuals and the percentage of each
species (%) for all passive surveillance bat submissions from 1976 to
2009
Species n submitted % Rabies positive
Barbastella barbastellus 3 0.4 0
Eptesicus nilssoni 13 1.6 0
Eptesicus serotinus 21 2.5 0
Hypsugo savii 1 0.1 0
Myotis bechsteini 5 0.6 0
Myotis blythii 2 0.2 0
Myotis daubentoni 64 7.6 3
Myotis myotis 41 4.9 0
Myotis mystacinus 45 5.4 0
Myotis nattereri 4 0.5 0
Myotis sp. 1 0.1 0
Nyctalus leisleri 21 2.5 0
Nyctalus noctula 68 8.1 0
Pipistrellus kuhli 57 6.8 0
Pipistrellus nathusii 112 13.4 0
Pipistrellus pipistrellus 224 26.8 0
Pipistrellus pygmaeus 11 1.3 0
Pipistrellus savii 2 0.2 0
Plecotus auritus 63 7.5 0
Plecotus austriacus 5 0.6 0
Plecotus macrobullaris 2 0.2 0
Plecotus sp. 3 0.4 0
Pipistrellus sp. 24 2.9 0
Vespertilio murinus 31 3.7 0
Unspecified 14 1.7
Total 837 100 3
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tested with EBLV-2b as the challenge virus (previously
isolated from one of the three positive Swiss Daubenton’s
bats, ID 1392/93), out of which 126 were tested at an initial
dilution of 1:25 and 35 at an initial dilution of 1:125.
Three bats, all Daubenton’s bats from different sampling
sites, were found to be seropositive. One specimen sampled
in Baulmes, Vaud, was positive with CVS (titre 1:56) but
could not be tested at the same initial dilution with EBLV-
2b (negative at 1:125 dilution). The other two seropositive
bats were sampled in Dorigny, Vaud (titre 1:70), and in
Genthod, Geneva (titre 1:314), and were found positive
with EBLV-2b but not with CVS as challenge virus. Fol-
lowing previous suggestions, we used a reciprocal titre of
C27 as the positive threshold [46].
Detection of EBLV RNA
A total of 237 bats, including 148 M. daubentoni, 51
M. myotis, 23 E. serotinus and 15 N. noctula, were ana-
lysed. Host GAPDH was detected in all of the swabs
analysed, indicating that material originating from the
sampled bat was present on the swab. No difference in the
ability to detect RNA in the wet or dry swabs was
observed. Both methods are therefore suitable to swab bats.
Of the 237 bats sampled, only one Daubenton’s bat (0.4%)
was found positive for EBLV-2b RNA by the nested PCR
approach, using both wet and dry swabs. Virus isolation
over four passages using RTCIT was negative with both
swabs. This bat was an adult female caught in Genthod in
the canton of Geneva. It was found to host nine parasitic
wing mites (Spinturnix andegavinus) and did not show any
signs of poor health or unusual behaviour.
Phylogenetic reconstruction
The two phylogenetic methods used, ML and BA, resulted
in similar tree topologies. The resulting phylogeny
obtained by BA analysis is presented in Fig. 2. The
sequence of the Daubenton’s bat sample (Genthod, canton
of Geneva) that was found to be positive in RT-PCR
(DEE70.SWI) grouped with the other three EBLV-2b
sequences identified previously in Swiss Daubenton’s bats,
particularly with the one that was found in the city of
Geneva in 2002 (118.SWI). The bootstrap support for the
subdivision of EBLV-2 in the lineages EBLV-2a and
EBLV-2b as suggested before [24] is reasonable (0.91 in
BA) but not overwhelming.
Discussion
The present study confirms the presence of EBLV-2 and
extends our knowledge about its epidemiology in the Swiss
bat population. The pattern of passive surveillance showed
clear drawbacks, both with respect to spatial distribution
Fig. 1 The distribution of
records across Switzerland from
passive bat rabies surveillance
(1967–2009). The most
frequently submitted species
and the positive cases are
indicated (including the two
major host species E. serotinus
and M. daubentoni). The
coordinates of individual
samples were shifted for clarity.
1 August 24, 1992,
M. daubentoni, Plaffeien,
Fribourg, 2 July 10, 1993,
M. daubentoni, Versoix,
Geneva, 3 September 2, 2002,
M. daubentoni, City of Geneva,
Geneva
Table 3 The number of individuals sampled around Lake Geneva
and close to Lake Neuchaˆtel, tested serologically (CVS/EBLVs) and
by RT-PCR for rabies, per site and per species of bats
Species n sites n sampled n RFITT/? n RT-PCR/?
M. daubentoni 9 148 124/3 148/1
M. myotis 4 51 47/0 51/0
N. noctula 2 15 14/0 15/0
E. serotinus 1 23 17/0 23/0
Total 237 202/3 237/1
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and the species representation of the main vectors E.
serotinus and M. daubentoni. During the passive surveil-
lance, three M. daubentoni were found to be positive for
EBLV-2, in 1992, 1993 and 2002. During the 4-month
targeted surveillance programme, seropositive healthy
Daubenton’s bats and a PCR-positive saliva of another
healthy Daubenton’s bat were found. This RT-PCR-posi-
tive bat was captured in Genthod, close to Versoix, where
the second case of EBLV in Swiss bats was detected in
1993. This sequence is closely related to the corresponding
sequences of the other three cases of EBLV-2 diagnosed in
Switzerland. Recently, EBVL-2 has also been detected in a
Daubenton’s bat in Germany [18].
Both the detection of neutralizing antibodies in blood
samples, indicating past exposure to EBLV, and the
detection of viral RNA in oropharyngeal swabs suggest
recent active circulation of EBLV in Swiss Daubenton’s
bats, confirming the potential for disease spread. Not a
single bat from the three other species sampled (Serotine
bat, Noctule bat and Great mouse-eared bat) gave a posi-
tive reaction by serology or RT-PCR. Out of the three
seropositive Daubenton’s bats, one was found positive with
CVS as challenge virus, probably due to serological cross-
reactivity with EBLVs. The other two samples were posi-
tive with EBLV-2b but not with CVS, indicating higher
sensitivity of the neutralization test when using EBLV as
the challenge virus. The seroprevalence over the different
Daubenton’s bats was 2.4% (3 of 24 bats tested), whereas
the prevalence estimated by RT-PCR was lower, with 0.7%
of individuals reacting positively (1/148). The low preva-
lence found in this work seems to be in accordance with the
north-to-south gradient in the frequency of EBLVs detec-
ted in Western Europe using classical techniques for viral
detection [47]. In Scotland, a seroprevalence of 0.05–3.8%
has been detected while screening M. daubentoni [48]. In a
recent active survey in England, a seroprevalence of 1.0–
4.1% was found, while no virus was detected using both
RT-PCR and RTCIT in 363 M. daubentoni bats sampled
[46].
EBLV-1 is the most common virus found across
northern and central Europe as far east as Russia, and in
western European countries as far south as Spain (reviewed
in ref. [49]). Germany and the Netherlands are the only
countries in which both EBLV-1 and EBLV-2 have been
detected. EBLV-1 has a specific association with the ser-
otine bat as the main vector, but it has also been reported in
greater mouse-eared bats in Spain [50, 51] and in noctule
bats in Germany [52]. Although serotine bats, noctule bats
and greater mouse-eared bats are frequently found across
Switzerland ([53] and Centre Suisse de Cartographie de la
Faune, Neuchaˆtel), few samples have been analysed
(Table 2) and none were found positive in the present
study. In view of regular cases encountered in serotine bats
both in France and Germany [13, 54], this infection may
have been missed in both passive and active surveillance so
far due to the limited number of individuals tested and the
biased distribution of sampling.
Appreciation of the potential for epidemiological spread
and disease risk requires an understanding of host dis-
persal. Seasonal movements of bats between summer and
winter roosts over hundreds of kilometres may provide
opportunities for disease spread. A noctule bat ringed in
Lausanne, Switzerland, was caught 670 km farther north,
near Leipzig, Germany (P. Christe, O. Glaizot, and
D. Brockmann, personal communication), and movements
up to 1,500 km have been recorded for this species [55].
A recent genetic study revealed a relative genetic unifor-
mity of UK and European continental Daubenton’s bat
populations, implying that there is no migration barrier to
EBLV-2 between regions [56]. Movement of bats over
long distances is therefore common and important with
respect to the epidemiology of EBLV, indicating a high
potential for spread of disease.
Conclusion
Overall, the results of this study suggest that the public-
health risk of infection with EBLV is moderate to low in
Switzerland. Nonetheless, the practice of considering
rabies in both humans and animals with a course of pro-
gressive encephalitis, also in the absence of a known
Fig. 2 Consensus Bayesian phylogenetic tree (50% majority consen-
sus) and branch length for partial nucleoprotein gene sequences from
GenBank, depicting the relationships of the Swiss isolates to other
isolates. The tree is rooted with two EBLV-1 samples. The results are
based on two runs of 5 9 106 generations, each with 4 chains
1660 A. Megali et al.
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history of exposure, must be maintained and ensured. The risk
of cross-species transmission to both humans and animals is
highest in clinically diseased, disoriented animals with bizarre
behaviour. EBLV-1 has not been detected in any of the
bats sampled, and EBLV-2 seems to be present only at a
very low prevalence. However, with the present confirmation
of EBLV-2 infection in Daubenton’s bats, and consider-
ing the biased sampling, the epidemic picture of EBLV in
Switzerland remains incomplete. Therefore, both active and
passive surveillance must be intensified in order to assess
more appropriately the potential risk to public health.
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